Beckley Psytech, an Oxford, England-based private company dedicated to addressing neurological and psychiatric disorders through the novel application of psychedelic medicines, closed an $80m Series B financing.
The round was led by Integrated, with participation from Prime Movers Labs, Adage Capital Management, Palo Santo; Delphi VC; Leafy Tunnel; Negev Capital; and existing investor Bicycle Day Ventures.
The company intends to use the funds to complete the ongoing Phase 1b trial with low-dose psilocybin in patients suffering from SUNHA, a rare and debilitating headache condition estimated to affect 45,000 people in the US and Europe, and to initiate a Phase 1 dose-ranging study on a novel formulation of intranasal 5-MeO-DMT before starting a Phase 2 trial in Treatment Resistant Depression, and expand its pipeline with new, unique and proprietary psychedelic compounds.
Led by Cosmo Feilding Mellen, CEO, Beckley Psytech is a clinical stage company dedicated to helping patients suffering from neurological and psychiatric disorders by developing a broad pipeline of psychedelic compounds in rare and more common diseases. Its vision is for clinically validated psychedelic medicines to be integrated into modern medical practice in order to help patients with high unmet medical need around the world, suffering from Short-lasting unilateral neuralgiform headache attacks (SUNHA), treatment resistant depression and other profoundly debilitating conditions.
FinSMEs
16/08/2021